Interstitial cystitis

Disease ID:506
Name:Interstitial cystitis
Associated with:2 targets
1 immuno-relevant targets
1 immuno-relevant ligands
Database Links
Disease Ontology: DOID:13949

Targets

FZD8
References:  1
INPP5D
Comments:  Phase 3 evaluating the SHIP1 activator rosiptor is underway (see NCT02858453).
Ligand interactions
Ligand Name Disease Association Comments Approved Primary Target Immuno
rosiptor
Phase 3 study for interstitial cystitis/bladder pain syndrome is ongoing (see NCT02858453).

Ligands

Ligand Approved Immuno References Clinical comments
rosiptor
Clinical Use: AQX-1125 has reached Phase 2 clinical trial in chronic inflammatory conditions such as unstable chronic obstructive pulmonary disease (COPD) and atopic dermatitis, and Phase 3 for interstitial cystitis/bladder pain syndrome [2] (see NCT02858453). Click here to link to ClinicalTrials.gov's full list of AQX-1125 trials.
Immuno Disease Comments: Phase 3 study for interstitial cystitis/bladder pain syndrome is ongoing (see NCT02858453).

References

Show »

1. Keay SK, Szekely Z, Conrads TP, Veenstra TD, Barchi Jr JJ, Zhang CO, Koch KR, Michejda CJ. (2004) An antiproliferative factor from interstitial cystitis patients is a frizzled 8 protein-related sialoglycopeptide. Proc. Natl. Acad. Sci. U.S.A., 101 (32): 11803-8. [PMID:15282374]

2. Nickel JC, Egerdie B, Davis E, Evans R, Mackenzie L, Shrewsbury SB. (2016) A Phase II Study of the Efficacy and Safety of the Novel Oral SHIP1 Activator AQX-1125 in Subjects with Moderate to Severe Interstitial Cystitis/Bladder Pain Syndrome. J. Urol., 196 (3): 747-54. [PMID:26968644]